GlassScriptPhysician profile
Jim N Hilepo
NPI 1679671317
$9,050.93
in general payments reported to CMS, 2019-2025
59 companies · $863 in 2025
The $863 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,940 · 2020: $978 · 2021: $1,353 · 2022: $1,799 · 2023: $1,016 · 2024: $1,102 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,581.05 |
| Education | $400.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $2,174.72 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $700.04 | 2019-2025 | Jynarque |
| Novo Nordisk INC | $661.77 | 2019-2025 | Wegovy |
| Amgen INC. | $535.77 | 2019-2025 | Prolia, Evenity, Aranesp |
| Novartis Pharmaceuticals Corporation | $533.88 | 2019-2025 | |
| Vifor Pharma, INC. | $531.58 | 2019-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $476.55 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $393.14 | 2019-2025 | |
| Lilly USA, LLC | $280.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Mallinckrodt Hospital Products INC. | $277.24 | 2020-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $212.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $174.97 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $166.98 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $146.33 | 2022-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $129.35 | 2021-2024 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Hilepo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.